Evidence map›Paper›PMID 39344744›Full record

ArticlePigment cell & melanoma research2025

Pathogenic Germline Variants in Uveal Melanoma Driver and BAP1-Associated Genes in Finnish Patients with Uveal Melanoma.

Pauliina E Repo, Eveliina Jakkula, Juho Hiltunen, Heidi Putkuri, Aleksandra Staskiewicz-Tuikkanen, Reetta-Stiina Järvinen, Martin Täll, Virpi Raivio, Rana'a T Al-Jamal, Tero T Kivelä and 1 more

Abstract read
In one paragraph

Article in Pigment cell & melanoma research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pauliina E RepoEye Genetics Group, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.ORCID 0000-0002-9257-9376
Eveliina JakkulaDepartment of Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Juho HiltunenEye Genetics Group, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.
Heidi PutkuriEye Genetics Group, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.
Aleksandra Staskiewicz-TuikkanenEye Genetics Group, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.
Reetta-Stiina JärvinenEye Genetics Group, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.
Martin TällOcular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Virpi RaivioOcular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Rana'a T Al-JamalOcular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tero T KiveläOcular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0003-1198-4394
Joni A TurunenEye Genetics Group, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.

Funding

Evald ja Hilda Nissin SäätiöHelsinki University Hospital Research FundMary och Georg C. Ehrnrooths StiftelseSilmä- ja kudospankkisäätiöSilmäsäätiöSyöpäsäätiö
6 · The paper itself

Abstract

Uveal melanoma (UM) is a rare yet aggressive eye cancer causing over 50% mortality from metastasis. Familial UM, amounting to 1%-6% of patients in Finland and the United States, mostly lack identified genetic cause, while 8% show associations with other cancer syndromes. We searched novel genetic associations for predisposition to UM, additional to already studied BAP1 and MBD4, by using targeted amplicon sequencing of 19 genes associated with UM, BAP1, or renal cell carcinoma in 270 consecutively enrolled Finnish patients with UM. Key UM drivers GNAQ, GNA11, CYSLTR2, PLCB4, EIF1AX, and SF3B1 lacked pathogenic germline variants. One patient carried the pathogenic BRCA1 variant c.3626del p.(Leu1209*), and one harbored a novel truncating MET variant c.252C > G p.(Tyr84*), classified as likely pathogenic. FLCN and BRCA2, previously identified with pathogenic variants in patients with UM, did not have such variants in our cohort. Two patients were heterozygous for a pathogenic recessive BLM variant c.2824-2A > T. None of the carriers of identified variants had familial UM. We identified BRCA1 and MET as genes with pathogenic germline variants in Finnish UM patients, each with a frequency of 0.4% (95% confidence interval, 0-2).

Indexed as

Germ-Line MutationMelanomaTumor Suppressor ProteinsUbiquitin ThiolesteraseUveal NeoplasmsAdultAgedFemaleFinlandGenetic Predisposition to DiseaseHumansMaleMiddle AgedUveal MelanomaBAP1 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1cancer syndromegenetic predispositionuveal melanoma

Identifiers

PMID39344744
PMCPMC11681845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.